**Facklamia Species as an Underrecognized Pathogen**

Elham Rahmati,1 Vanessa Martin,2 Darren Wong,1 Fred Sattler,1 Jonas Pettersson,1 Pamela Ward,1 Susan M. Butler-Wu,2 and Rosemary C. She2

1Department of Medicine, Division of Infectious Diseases and 2Department of Pathology, 3Keck Medical Center of the University of Southern California, Los Angeles

**Facklamia** species are rarely reported etiology of clinical infection with few cases described in literature. However, the prevalence of infection may be underestimated due to challenges in species identification. We describe 3 cases of **Facklamia** species bacteremia and the unique microbiologic aspects inherent to this genus that make it particularly challenging to identify. In addition, given the unique susceptibility profile of **Facklamia** species, we discuss the importance of fully identifying this organism when it is a suspected as a pathogen, to optimize therapy based on its distinct antibiotic resistance profile.

**Keywords.** bloodstream infection; **Facklamia;** 16S rRNA sequencing; susceptibility.

**Facklamia** species are Gram-positive, α-hemolytic, catalase-negative, facultative anaerobic cocci that remain challenging to accurately identify with current microbiologic identification systems. We describe 3 cases of **Facklamia** spp bacteremia to illustrate the pitfalls in laboratory identification of this genus.

**CASE ONE**

A 64-year-old homeless male with history of active intravenous drug use was found unresponsive in a nearby street surrounded by needles. On admission, he was hypothermic with leukocytosis of 21 K/µL. Two of 2 blood culture sets isolated Gram-positive cocci in chains after 72 hours. Colonies were pinpoint, sticky, pyrrolidonyl arylamidase (PYR)-negative, and α-hemolytic with no zone around A- or P-disks and with better growth in ambient air than 5% CO2. The organism was initially reported as viridans group Streptococcus (VGS). Susceptibility by E-test per manufacturer’s recommendations for VGS (AB Biodisk, Solna, Sweden) was read at 48 hours due to poor growth. The pattern was unusual with elevated minimal inhibitory concentrations (MICs) to cefotaxime (32 µg/mL) and penicillin (4 µg/mL), later confirmed by broth microdilution method at a reference laboratory (Table 1). Matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry (Vitek MS; bioMerieux, Durham, NC) yielded no identification. Transthoracic echocardiogram and subsequent cardiac magnetic resonance imaging demonstrated an extensive 5.3 × 3.8 × 2.2-cm left atrial mass involving the anterior mitral valve leaflet. He was a high-risk surgical candidate and managed medically. With limited microbiologic data, the patient was treated with 6-weeks of vancomycin and gentamicin similar to treatment for penicillin-resistant enterococci. Sequencing of the first 500 base pairs of the 16S recombinant ribonucleic acid (rRNA) gene was performed, which yielded an identification of **Facklamia ignava** (99.2% identity to American Type Culture Collection [ATCC] 700631 with 4 ambiguous base pairs) [1]. The patient remained clinically stable after 6 months but refused further cardiac imaging as recommended.

**CASE TWO**

A 36-year-old male was admitted for suicide attempt with overdose on antidepressants. He developed acute respiratory distress syndrome from aspiration pneumonia after an observed seizure requiring intubation. Blood cultures were drawn 2 weeks after admission for fever and leukocytosis. One of 2 sets became positive after 3 days for Gram-positive cocci in chains for which he was treated with vancomycin. Colonies were pinpoint after 24 hours, non-hemolytic, and PYR-negative. The MALDI-TOF mass spectrometry identified the isolate as Abiotrophia defectiva (95% confidence). However, the organism displayed better growth on sheep blood than chocolate agar, a finding atypical for Abiotrophia species. 16S rRNA gene sequencing performed at a reference laboratory revealed the true organism identity as **Facklamia languida**. Broth microdilution susceptibility testing showed elevated MICs to cefepime, ceftriaxone, and ertapenem (Table 1). Transthoracic echocardiogram revealed no evidence of valvular vegetation. Two subsequent blood cultures were negative. The patient expired from respiratory failure 4 weeks after admission.

**CASE THREE**

A 59-year-old female with diabetes, chronic kidney disease requiring hemodialysis, and nonalcoholic cirrhosis with refractory ascites was admitted with abdominal pain. She denied fevers or chills. Blood cultures at the time of admission were positive after 2 days, isolating Staphylococcus aureus, Peptostreptococcus anaerobius, and a Gram-positive coccus in chains. The latter grew...
in 1 aerobic bottle of 3 sets and was PYR-positive, pinpoint, and non-hemolytic on sheep blood agar. It could not be identified biochemically (RapID Strep; Remel, Lexington, KY) and was referred for 16S rRNA gene sequencing and broth microdilution susceptibility testing. It was identified as *F. languida* remarkable for an elevated MIC to ceftriaxone (Table 1). Abdominal fluid cultures also grew *S. aureus*. The patient was initially treated with vancomycin, cefepime, and metronidazole. Her antibiotic regimen was further activated MIC to ceftriaxone (Table 1). Abdominal fluid cultures also identified MIC to ceftriaxone. The patient was later treated with linezolid and ceftriaxone.

### DISCUSSION

The genus *Facklamia* was first described in 1997 using 16S rRNA sequencing and has since been identified from both a wide range of animal sources and in humans as a human pathogen [2–4]. Bacteremia has been associated with endocarditis, necrotizing gangrene, chorioamnionitis, and central nervous system disease [5–9]. Only 2 cases of possible *F. ignava* infection have been reported [10], and we add a case in which it was a likely contributor to a case of endocarditis.

Although *Facklamia* spp have been implicated in invasive infections, the virulence of this organism has not been fully determined. The true extent of morbidity and mortality is further convoluted not only by the relative scarcity of reported cases, but also by the co-occurrence of *Facklamia* with other bacteria and often in patients with significant comorbidities. In addition to blood cultures, *Facklamia* has been isolated from vaginal specimens, urine, cerebrospinal fluid, bone, skin, and gall bladder [11, 12]. Because the majority of collected specimens have been from women, it has been speculated that this organism may be normal flora in the female genital tract [11, 12]. However, based on our case series, we are unable to exclude the possibility that *Facklamia* may have originated from other sources such as the gastrointestinal tract or skin.

Similar to other uncommon *Streptococcus*-like organisms that may be isolated from clinical specimens, such as *Dolosigranulum, Inavigranum*, or *Vagococcus* spp, the clinical significance of *Facklamia* spp is not well understood. Although it is conceivable that all 3 of our cases of *Facklamia* isolated from blood were true pathogens, we cannot establish with absolute certainty that this organism significantly contributed to the clinical outcome of our patients. This is particularly challenging in cases 2 and 3 because *Facklamia* was only isolated from 1 set of blood cultures, which could be interpreted as contamination. On the other hand, our first case demonstrated multiple positive blood culture sets for *Facklamia* in the setting of endocarditis, which compels us to believe that *Facklamia* does have pathogenic potential.

*Facklamia* species are easily misidentified by traditional laboratory methods [13]. In contrast, organisms have been erroneously identified as *Facklamia* only to be later identified as *Enterococcus faecalis*, *Cardiobacterium valvarum*, or *Streptococcus mutans* by 16S rRNA gene sequencing [1]. *Facklamia* spp are similar to *VGS* in Gram stain, colony morphology, and catalase reaction. However, *Facklamia* spp are usually PYR-positive [10, 13], although in 2 of our cases this was not true. In each case, *Facklamia* spp grew fastidiously, requiring at least 2–3 days for blood culture bottles to flag positive. With the v2.0 Knowledge Base, the Vitek MS was unable to provide identification for *F. ignava* and misidentified *F. languida* as *A. deflectiva*. *Facklamia* spp are also not currently claimed in the Bruker Biotyper MALDI-TOF system. This underscores the continuing need for bench microbiologist expertise in spite of advances in technology. With limited experience in *Facklamia* identification for most laboratories, it appears at the current time that definitive identification is best made by deoxyribonucleic acid sequence analysis.

It is important to distinguish *Facklamia* spp from *VGS* and *Streptococcus*-like organisms because of its unusual susceptibility profile. Limited antimicrobial susceptibility studies have shown *F. ignava* and *F. languida* isolates to possess elevated MICs to cefotaxime, erythromycin, clindamycin, and trimethoprim-sulfamethoxazole and low MICs to levofloxacin and vancomycin. *Facklamia ignava*, but not *F. languida*, may have elevated penicillin MICs. For *F. languida*, elevated carbapenem MICs have also been observed [12]. Recognition of the susceptibility profiles for *Facklamia* spp could help in raising suspicion if the organisms were misidentified, eg, as *VGS* or *Abiotrophia* spp cases of *Facklamia* spp bacteremia with associated necrotizing gangrene, chorioamnionitis, and central nervous system disease were previously treated effectively with vancomycin, amoxicillin/clavulanic acid, and ceftriaxone plus vancomycin, respectively [5, 7, 9]. Endocarditis due to *Facklamia* spp has only been described in 2 cases of *Facklamia hominis* where 1 case was treated successfully with ceftriaxone and gentamicin [6] and 1 case resulted in fatal myocardial infarction despite 2

---

**Table 1. MIC (μg/mL) of the Three *Facklamia* spp Cases Based on Broth Microdilution Method**

| Antibiotics       | Case 1 *Facklamia ignava* | Case 2 *Facklamia languida* | Case 3 *F. languida* |
|-------------------|---------------------------|----------------------------|---------------------|
| Penicillin        | 1 (I)                     | 0.06 (S)                   | 0.06 (S)            |
| Ceftriaxone       | >2 (R)                    | >2 (R)                     | >2 (R)              |
| Cefepime          | 2 (I)                     | 4 (R)                      | 2 (I)               |
| Vancomycin        | ≤0.5 (S)                  | ≤0.5 (S)                   | ≤0.5 (S)            |
| Ertapenem         | ≤0.5 (S)                  | 4 (NS)                     | 4 (NS)              |
| Levofloxacin      | >4 (R)                    | ≤0.5 (S)                   | 4 (I)               |
| Erythromycin      | ≤0.25 (S)                 | 0.5 (I)                    | >2 (R)              |
| Daptomycin        | 0.12 (S)                  | 0.25 (S)                   | 0.12 (S)            |

Abbreviations: I, intermediate; MIC, minimal inhibitory concentrations; NS, nonsusceptible; R, resistant; S, susceptible.

*Interpretations given in parentheses are based on standard guidelines for viridans group streptococci [14].*
days of vancomycin and gentamicin [8]. Because there are no guidelines for treatment of *Facklamia* spp bacteremia, clinical decisions must be made based on data from nonstandardized susceptibility testing; empiric treatment with vancomycin would be appropriate given the variable susceptibility profiles of *Facklamia* to β-lactam drugs. Based on limited published clinical experience and our own case, for *Facklamia* endocarditis, treatment with 6 weeks of β-lactam antibiotic or vancomycin with 2 weeks of gentamicin may be a reasonable choice.

**CONCLUSIONS**

*Facklamia* spp are organisms whose true virulence and pathogenesis are poorly understood. They may cause infection in a susceptible host, but clarifying the risk factors has proven to be difficult based on the scarcity of literature. Due to challenges in its identification, the true burden of disease may be underestimated. However, the importance of appropriate identification should not be discounted because susceptibilities for *Facklamia* may differ significantly from the VGS for which it may be misidentified. This potential resistance to β-lactams may have significant clinical treatment implications.

**Acknowledgment**

**Potential conflicts of interest.** All authors: No reported conflicts. All authors have submitted the ICMJE Form for Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Petri CA, Polage CR, Schreckenberger P. The role of 16S rRNA gene sequencing in identification of microorganisms misidentified by conventional methods. J Clin Microbiol 2005; 43:6123–5.

2. Collins MD, Falsen E, Lemozy J, et al. Phenotypic and phylogenetic characterization of some *Globicatella*-like organisms from human sources: description of *Facklamia hominis* gen. nov., sp. nov. Int J Syst Bacteriol 1997; 47:880–2.

3. Hoyles L, Foster G, Falsen E, et al. *Facklamia miroungae* sp. nov., from a juvenile southern elephant seal (*Mirounga leonina*). Int J Syst Evol Microbiol 2001; 51:1401–3.

4. Takamatsu D, Ide H, Osaki M, Sekizaki T. Identification of *Facklamia sourekii* from a lactating cow. J Vet Med Sci 2006; 68:1225–7.

5. Pérez Alonso AJ, Husein El Ahmed H, Del Olmo Rivas C, et al. *Facklamia sourekii* necrotizing gangrene. Med Mal Infect 2012; 42:283–4.

6. Ananthakrishna R, Shankarappa RK, Jagadeesan N, et al. Infective endocarditis: a rare organism in an uncommon setting. Case Rep Infect Dis 2012; 2012:367852.

7. Healy B, Beekenholt RW, Tuthill D, Ribeiro CD. *Facklamia hominis* causing chorioamnionitis and puerperal bacteraemia. J Infect 2005; 50:353–5.

8. Safavi S, Tufnell M, Bhalla A. Multi-territory ischaemic strokes and subacute bacterial endocarditis. BMJ Case Rep 2010; 2010 pii: bcr0620092023.

9. McCann E, Barber M, Hunter P, Inverarity D. A very unusual organism causing stroke-like symptoms. Age Ageing 2014; 43:727–8.

10. Collins MD, Lawson PA, Monasterio R, et al. *Facklamia ignava* sp. nov., isolated from human clinical specimens. J Clin Microbiol 1998; 36:2146–8.

11. Parvataneni KC, Iyer S, Khatib R, Saravolatz LD. *Facklamia* species and *Streptococcus pneumoniae* meningitis: a case report and review of the literature. Open Forum Infect Dis 2015; 2:ofv029.

12. LaClaire L, Facklam R. Antimicrobial susceptibilities and clinical sources of *Facklamia* species. Antimicrob Agents Chemother 2000; 44:2130–2.

13. LaClaire LL, Facklam RR. Comparison of three commercial rapid identification systems for the unusual Gram-positive cocci *Dolosigranulum pigrum*, *Ignavigranum ruoffiae*, and *Facklamia* species. J Clin Microbiol 2000; 38:2037–42.

14. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*. 26th ed. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.